GRAIL Investors File Class Action After $2.2 Billion Market Wipeout
A staggering $2.2 billion evaporated from GRAIL, Inc.’s market capitalization on February 20, 2026, after the healthcare company revealed that its high-profile NHS-Galleri trial failed to meet primary endpoints, triggering a securities class action lawsuit against the firm and its executive leadership.
The litigation, spearheaded by Hagens Berman, targets the period between May 13, 2025, and February 19, 2026. Investors allege that company leadership misled the market by projecting confidence in the trial’s three-year design, despite possessing internal information that such a duration was insufficient to demonstrate a statistically significant reduction in late-stage cancer diagnoses. The share price plummeted over 50% immediately following the disclosure.
Hagens Berman partner Reed Kathrein is now investigating whether management knowingly ignored the limitations of the trial’s timeline while maintaining a facade of optimism. The firm is currently soliciting input from investors who suffered substantial losses and is seeking whistleblowers with non-public information regarding the trial’s design flaws. The deadline for investors to serve as lead plaintiff is August 4, 2026.
Comments (0)
No comments yet. Be the first!